Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly said on Monday it would allow a limited number of patients ​to have early access to its experimental obesity drug, ‌retatrutide, before its U.S. FDA approval.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。